ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific OfficerARTBIO | October 5, 2023
Emanuele Ostuni, PhD
We are identifying specific combinations of targets and drug molecules best suited for ART. Our ARTs have high affinity and selectivity in order to effectively kill tumors while sparing healthy tissues.
ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy. Born out of groundbreaking research conducted at the University of Oslo and Norway’s Radium Hospital - a research hub with lineage to Marie Curie - ARTBIO’s roots in radiology and radiation therapy run deep. Our scientific founders, Roy Larsen and Øyvind Bruland, invented Xofigo (later acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy. Both collaborated with the F-Prime team and Radforsk to lay the foundation of ARTBIO in 2021.
Our team is composed of multi-disciplinary experts with decades of experience in advancing complex drugs through all stages of clinical development. We are driven by the power of collective thinking, diversity, and a passion to create smarter solutions together. Finally, we take pride in combining creativity and scientific expertise to address challenges. We value inclusion, collaboration, and fostering strong relationships with our team, partners, health care.